Entera Bio Ltd. (NASDAQ:ENTX) to Post Q1 2024 Earnings of ($0.23) Per Share, HC Wainwright Forecasts

Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Entera Bio in a research report issued to clients and investors on Tuesday, April 4th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.23) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Entera Bio’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Entera Bio’s Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.21) EPS and FY2024 earnings at ($0.92) EPS.

Get Entera Bio alerts:

Entera Bio Trading Down 6.1 %

ENTX stock opened at $0.92 on Wednesday. The stock has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $0.88. The stock has a market cap of $26.50 million, a PE ratio of -2.04 and a beta of 1.83. Entera Bio has a 1 year low of $0.47 and a 1 year high of $3.00.

Hedge Funds Weigh In On Entera Bio

A number of large investors have recently added to or reduced their stakes in ENTX. PNC Financial Services Group Inc. bought a new position in Entera Bio during the 1st quarter worth about $29,000. Millennium Management LLC grew its holdings in shares of Entera Bio by 358.5% in the 4th quarter. Millennium Management LLC now owns 46,000 shares of the company’s stock valued at $34,000 after acquiring an additional 35,968 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 555.4% in the 4th quarter. Renaissance Technologies LLC now owns 139,600 shares of the company’s stock valued at $102,000 after acquiring an additional 118,300 shares in the last quarter. Institutional investors own 20.12% of the company’s stock.

About Entera Bio

(Get Rating)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Recommended Stories

• Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
• Penny Stock Wag! Group Co. Has Solid Sell-Side Support
• Staples Stocks Get Lift From Conagra Results, New Highs In Sight
• SGH Bottomed, But Can It Reverse And Move Higher? 
• Is Pinterest Showing Signs of an Improving Ad Market?
• At 3x Earnings, Avis Budget Is Worth Taking for a Spin

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.